comparemela.com

Latest Breaking News On - Jude onyia - Page 1 : comparemela.com

Neurocrine Biosciences (NASDAQ:NBIX) Given New $148.00 Price Target at JPMorgan Chase & Co.

Neurocrine Biosciences (NASDAQ:NBIX – Free Report) had its price objective cut by JPMorgan Chase & Co. from $154.00 to $148.00 in a report published on Friday, Benzinga reports. They currently have an overweight rating on the stock. Several other research analysts have also weighed in on the stock. Raymond James upped their price objective on […]

Canada
United-states
Neurocrine-biosciences
Jude-onyia
Piper-sandler
Raymond-james
Matt-abernethy
Edgerock-capital
Neurocrine-biosciences-company-profile
Citigroup
Benjaminf-edwards-company-inc
Securities-exchange-commission

Texas Permanent School Fund Corp Sells 2,978 Shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX)

Texas Permanent School Fund Corp lessened its position in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Free Report) by 3.5% in the third quarter, according to its most recent filing with the SEC. The firm owned 82,935 shares of the company’s stock after selling 2,978 shares during the quarter. Texas Permanent School Fund Corp owned […]

Canada
Texas
United-states
Darin-lippoldt
Jude-onyia
Raymond-james
Neurocrine-biosciences
Texas-permanent-school-fund-corp
Nasdaq
Rice-hall-james-associates
Financial-services-group-inc
Dimensional-fund-advisors

Oppenheimer Asset Management Inc. Has $1.79 Million Position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX)

Oppenheimer Asset Management Inc. boosted its position in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Free Report) by 12.2% during the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 15,929 shares of the company’s stock after buying an additional 1,736 shares during the period. Oppenheimer […]

Darin-lippoldt
Neurocrine-biosciences
Jude-onyia
Piper-sandler
Neurocrine-biosciences-inc
Wells-fargo-company
Securities-exchange-commission
Ieq-capital
Blackrock-inc
Norges-bank
Neurocrine-biosciences-company-profile
Oppenheimer-asset-management-inc

Neurocrine Biosciences (NASDAQ:NBIX) PT Raised to $153.00

Neurocrine Biosciences (NASDAQ:NBIX – Get Free Report) had its price objective hoisted by The Goldman Sachs Group from $134.00 to $153.00 in a research report issued to clients and investors on Thursday, Benzinga reports. The firm presently has a “buy” rating on the stock. The Goldman Sachs Group’s price target indicates a potential upside of […]

Eiry-roberts
Robertw-baird
Neurocrine-biosciences
Jude-onyia
Goldman-sachs-group
Nasdaq
Raymond-james-financial-services-advisors-inc
Neurocrine-biosciences-inc
Securities-exchange-commission
Red-spruce-capital
Sunbelt-securities-inc
Metis-global-partners

Biocytogen Enters into Multi-Target Antibody Agreement with Neurocrine Biosciences

Biocytogen Enters into Multi-Target Antibody Agreement with Neurocrine Biosciences
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

San-francisco
California
United-states
Shanghai
China
Beijing
Haimen-jiangsu
Jude-onyia
Yuelei-shen
Neurocrine-biosciences
Biocytogen-pharmaceuticals-beijing-co-ltd
Neurocrine-biosciences-inc

vimarsana © 2020. All Rights Reserved.